← Human Trials & Peer-Reviewed Studies
Feasibility and preliminary biomarker responses to capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus: a randomized, placebo-controlled pilot trial.
Plain-language guide to PMID 42531580 (2026): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 48 women.
Key Facts
- PMID
- 42531580
- Journal
- Revista peruana de medicina experimental y salud publica
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Moura de Araújo MF et al. (10 authors)
- DOI
- 10.17843/rpmesp.2026.432.15505
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
To evaluate the feasibility of a 12-week, randomized, double-blind, placebo-controlled intervention with capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus, including overall adherence to capsule use and tolerability, as well as to explore preliminary between-group differences in glycemic and cardiovascular biomarkers.
Who Took Part
The study group was 48 women.
PubMed indexes the participants as middle-aged adults, women only.
This randomized, double-blind, placebo-controlled pilot trial included 48 eligible women with type 2 diabetes mellitus, equally assigned to the placebo group (n=24) or the experimental group (n=24).
Data were analyzed based on avail-able data from participants who completed follow-up and the final evaluation.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Glycemic biomarkers included fasting glucose, estimated mean glucose, HbA1c, insulin, HOMA-IR, and HOMA-β.
Cardiovascular biomarkers included urea, creatinine, uric acid, apolipoprotein B, triglycerides, and the triglycerides-glucose index.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 2, Pilot Projects, Biomarkers, Feasibility Studies, Coffee, Plant Extracts and Malates.
Author keywords: Blood Glucose, Insulin and Magnesium.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 48 women.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Revista peruana de medicina experimental y salud publica), a journal based in Peru.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.